ERBB2 and breast cancer: Triple-negative breast cancer (TNBC), defined by the absence (or relative low expression) of the estrogen and progesterone receptors (ER and PR, respectively) and of human epidermal growth factor receptor 2 (HER2), accounts for 15-20% of all breast cancer cases (Foulkes et al., 2010).